NASDAQ:TSVT 2seventy bio (TSVT) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free TSVT Stock Alerts $4.35 -0.28 (-6.05%) (As of 01:53 PM ET) Add Compare Share Share Today's Range$4.28▼$4.7450-Day Range$3.96▼$6.0052-Week Range$1.53▼$12.69Volume288,809 shsAverage Volume1.36 million shsMarket Capitalization$223.20 millionP/E RatioN/ADividend YieldN/APrice Target$13.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get 2seventy bio alerts: Email Address 2seventy bio MarketRank™ Stock AnalysisAnalyst RatingHold2.38 Rating ScoreUpside/Downside202.7% Upside$13.17 Price TargetShort InterestBearish14.29% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$3.14 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.39) to $0.07 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.28 out of 5 starsMedical Sector295th out of 909 stocksPharmaceutical Preparations Industry127th out of 423 stocks 4.2 Analyst's Opinion Consensus Rating2seventy bio has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 3 buy ratings, 5 hold ratings, and no sell ratings.Amount of Analyst Coverage2seventy bio has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted14.29% of the float of 2seventy bio has been sold short.Short Interest Ratio / Days to Cover2seventy bio has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in 2seventy bio has recently increased by 29.71%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend Yield2seventy bio does not currently pay a dividend.Dividend Growth2seventy bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TSVT. Previous Next 2.5 News and Social Media Coverage News Sentiment2seventy bio has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.Search Interest19 people have searched for TSVT on MarketBeat in the last 30 days. This is an increase of 27% compared to the previous 30 days.MarketBeat Follows5 people have added 2seventy bio to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, 2seventy bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $3,143,100.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.60% of the stock of 2seventy bio is held by insiders.Percentage Held by Institutions93.90% of the stock of 2seventy bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for 2seventy bio are expected to grow in the coming year, from ($1.39) to $0.07 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 2seventy bio is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 2seventy bio is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio2seventy bio has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About 2seventy bio Stock (NASDAQ:TSVT)2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.Read More TSVT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TSVT Stock News HeadlinesMarch 26, 2024 | insidertrades.comInsider Buying: 2seventy bio, Inc. (NASDAQ:TSVT) Director Buys 300,000 Shares of StockApril 17, 2024 | msn.com2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's WhyApril 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 15, 2024 | americanbankingnews.com2seventy bio, Inc. (NASDAQ:TSVT) Short Interest Up 29.7% in MarchApril 13, 2024 | morningstar.com2seventy bio Inc Ordinary SharesApril 10, 2024 | investing.comCiti raises 2Seventy Bio stock target on FDA approvalApril 8, 2024 | markets.businessinsider.comPositive Outlook for 2seventy bio’s ABECMA: Buy Rating Affirmed Amidst Expansion and Competitive DynamicsApril 7, 2024 | markets.businessinsider.comBuy Rating and High Risk for 2seventy bio: FDA Approval and Market Expansion Fuel Optimistic OutlookApril 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 5, 2024 | msn.comBristol Myers Wins FDA Nod for AbecmaApril 5, 2024 | msn.comFDA Approves Bristol-Myers/2seventy Bio's Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary CancerApril 5, 2024 | seekingalpha.comBristol Myers, 2seventy bio's Abecma approved for earlier line multiple myelomaApril 5, 2024 | finance.yahoo.comU.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of TherapyMarch 20, 2024 | msn.com2seventy bio appoints Eli Casdin and Charles Newton to its board of directorsMarch 20, 2024 | businesswire.com2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of DirectorsMarch 20, 2024 | morningstar.comThinking about buying stock in 2Seventy Bio, Verb Technology, Exscientia, MicroCloud Hologram, or Akebia Therapeutics?March 17, 2024 | marketwatch.comBristol Myers, 2seventy Bio's Cancer Treatment Wins FDA Committee ApprovalMarch 16, 2024 | msn.comBristol Myers wins FDA AdCom backing for Abecma label expansionMarch 15, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: 2seventy bio (TSVT), Immuneering (IMRX)March 14, 2024 | marketwatch.com2seventy Bio Shares Fall on Concerns About FDA Panel's Meeting on Abecma Gene TherapyMarch 7, 2024 | seekingalpha.com2Seventy Bio, Inc. (TSVT) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | msn.com2seventy bio, Inc. (NASDAQ:TSVT) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for 2seventy bio on FDA Meeting and Strong Financial OutlookMarch 7, 2024 | finance.yahoo.comDowngrade: Here's How Analysts See 2seventy bio, Inc. (NASDAQ:TSVT) Performing In The Near TermMarch 6, 2024 | finance.yahoo.comWhen Will 2seventy bio, Inc. (NASDAQ:TSVT) Turn A Profit?March 5, 2024 | investorplace.comTSVT Stock Earnings: 2seventy bio Misses EPS, Misses Revenue for Q4 2023March 5, 2024 | finance.yahoo.com2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational ProgressSee More Headlines Receive TSVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 2seventy bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2024Today4/24/2024Next Earnings (Estimated)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TSVT CUSIPN/A CIK1860782 Webwww.2seventybio.com Phone339-499-9300FaxN/AEmployees274Year FoundedN/APrice Target and Rating Average Stock Price Target$13.17 High Stock Price Target$26.00 Low Stock Price Target$5.00 Potential Upside/Downside+184.4%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($4.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-217,570,000.00 Net Margins-216.73% Pretax Margin-216.73% Return on Equity-59.19% Return on Assets-29.67% Debt Debt-to-Equity RatioN/A Current Ratio3.98 Quick Ratio3.98 Sales & Book Value Annual Sales$100.39 million Price / Sales2.37 Cash FlowN/A Price / Cash FlowN/A Book Value$5.04 per share Price / Book0.92Miscellaneous Outstanding Shares51,310,000Free Float49,977,000Market Cap$237.57 million OptionableOptionable Beta1.84 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Nick Leschly (Age 51)President & Director Comp: $1.81MDr. Philip D. Gregory D. Phil. (Age 53)DPHIL, Chief Scientific Officer Comp: $1.01MMr. William D. Baird III (Age 52)M.B.A., Chief Executive Officer Comp: $810.83kVicki EatwellChief Financial OfficerJessica SnowSenior VP of Quality and Head of OperationsMs. Susan Abu-Absi Ph.D.Chief Technology OfficerMs. Teresa L. Jurgensen J.D.Senior VP, General Counsel & Corporate SecretaryMs. Kerri JensenHead of People & CultureMs. Jenn SnyderSenior Vice President of Corporate AffairsDr. Steven Bernstein M.D.Chief Medical OfficerMore ExecutivesKey Competitors23andMeNASDAQ:MEAC ImmuneNASDAQ:ACIUVerastemNASDAQ:VSTMAldeyra TherapeuticsNASDAQ:ALDXConduit PharmaceuticalsNASDAQ:CDTView All CompetitorsInsiders & InstitutionsWedmont Private CapitalBought 85,934 shares on 4/10/2024Ownership: 0.167%Casdin Capital, LlcBought 330,000 shares on 3/25/2024Total: $1.67 M ($5.07/share)Casdin Capital, LlcBought 300,000 shares on 3/21/2024Total: $1.47 M ($4.90/share)Wellington Management Group LLPSold 2,478,516 shares on 3/5/2024Ownership: 1.019%Goldman Sachs Group Inc.Bought 3,772,556 shares on 3/1/2024Ownership: 8.907%View All Insider TransactionsView All Institutional Transactions TSVT Stock Analysis - Frequently Asked Questions Should I buy or sell 2seventy bio stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 2seventy bio in the last year. There are currently 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TSVT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TSVT, but not buy additional shares or sell existing shares. View TSVT analyst ratings or view top-rated stocks. What is 2seventy bio's stock price target for 2024? 8 analysts have issued 12 month target prices for 2seventy bio's shares. Their TSVT share price targets range from $5.00 to $26.00. On average, they anticipate the company's share price to reach $13.17 in the next year. This suggests a possible upside of 202.7% from the stock's current price. View analysts price targets for TSVT or view top-rated stocks among Wall Street analysts. How have TSVT shares performed in 2024? 2seventy bio's stock was trading at $4.27 at the start of the year. Since then, TSVT stock has increased by 1.9% and is now trading at $4.35. View the best growth stocks for 2024 here. Are investors shorting 2seventy bio? 2seventy bio saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 6,810,000 shares, an increase of 29.7% from the March 15th total of 5,250,000 shares. Based on an average daily volume of 1,450,000 shares, the short-interest ratio is presently 4.7 days. Currently, 14.3% of the company's stock are sold short. View 2seventy bio's Short Interest. When is 2seventy bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our TSVT earnings forecast. How were 2seventy bio's earnings last quarter? 2seventy bio, Inc. (NASDAQ:TSVT) issued its earnings results on Tuesday, March, 5th. The company reported ($1.11) EPS for the quarter, beating analysts' consensus estimates of ($1.22) by $0.11. The company earned $10.68 million during the quarter, compared to the consensus estimate of $13.91 million. 2seventy bio had a negative net margin of 216.73% and a negative trailing twelve-month return on equity of 59.19%. During the same period in the previous year, the firm posted ($0.60) earnings per share. What ETFs hold 2seventy bio's stock? ETFs with the largest weight of 2seventy bio (NASDAQ:TSVT) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), Range Cancer Therapeutics ETF (CNCR), Loncar China Biopharma ETF (CHNA) and Horizon Kinetics Medical ETF (MEDX).Global X Genomics & Biotechnology ETF (GNOM). Who are 2seventy bio's major shareholders? 2seventy bio's stock is owned by many different retail and institutional investors. Top institutional investors include Wedmont Private Capital (0.17%). Insiders that own company stock include Casdin Capital, Llc, Kynam Capital Management, Lp, Nick Leschly, Nicola Heffron, Philip D Gregory and William D Baird III. View institutional ownership trends. How do I buy shares of 2seventy bio? Shares of TSVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TSVT) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe #1 Crypto for 2024InvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe Greatest Bull Market in Crypto History…Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 2seventy bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
